Health Trials

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

ConditionsMetastatic Cervical CancerPersistent Cervical CancerRecurrent Cervical Cancer
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorN.N. Alexandrov National Cancer Centre

About this trial

This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.

Eligibility criteria

Qualifiers

Age ≥18-≤75 years.

Histologically confirmed diagnosis.

Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);

Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);

Disqualifiers

Presence of another active malignant invasive neoplasm.

Pregnancy or lactation period.

Trial design

Treatments tested in this trial

  • PD-1 antibody
  • PD-L1 antibody
  • Chemotherapy and bevacizumab (CT-BEV)

Treatment groups

120 Participants
are divided into 3 treatment groups

Sponsors and collaborators

N.N. Alexandrov National Cancer Centre

Lead sponsor

Source ClinicalTrials.gov